<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186108</url>
  </required_header>
  <id_info>
    <org_study_id>PROS0006</org_study_id>
    <nct_id>NCT00186108</nct_id>
  </id_info>
  <brief_title>A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer</brief_title>
  <official_title>A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the ability of oral triamcinalone given&#xD;
      twice a day to patients with androgen independent prostate cancer to produce a sustained&#xD;
      biochemical response. Secondary goals are to describe the safety and tolerability at this&#xD;
      dose and schedule, to determine the time to sustained biochemical response, to determine the&#xD;
      duration of biochemical response, to determine the time to disease progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of oral triamcinalone given twice a day to patients with androgen independent prostate cancer to produce a sustained biochemical response.</measure>
    <time_frame>Following treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability at this dose and schedule, time to sustained biochemical response, duration of biochemical response, time to disease progression</measure>
    <time_frame>Following treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Triamcinalone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  Histologically documented adenocarcinoma of prostate&#xD;
&#xD;
          -  Currently receiving LHRH agonists with castrate levels of testosterone or who have had&#xD;
             an orchiectomy&#xD;
&#xD;
          -  Must have had a rise in PSA despite anti androgen withdrawal&#xD;
&#xD;
          -  Exhibit 2 consecutive rise in PSA after the last hormonal manipulation&#xD;
&#xD;
          -  Minimum PSA of greater than 5 KPS greater than 80%&#xD;
&#xD;
          -  Normal cortisol level at entry&#xD;
&#xD;
          -  Life expectancy greater than 6 months&#xD;
&#xD;
          -  Provide written consent pursuant to regulatory requirements prior to initiation of&#xD;
             study procedure&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Younger than 18 years&#xD;
&#xD;
          -  Patients without prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandy Srinivas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>July 24, 2007</last_update_submitted>
  <last_update_submitted_qc>July 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2007</last_update_posted>
  <keyword>Oral Triamcinalone</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

